ClinicalTrials.Veeva

Menu

Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies (IBVM/DATSCAN)

U

University Hospital of Bordeaux

Status

Completed

Conditions

Dementia With Lewy Bodies

Treatments

Other: Imaging with IBVM
Other: Imaging with DATSCAN
Behavioral: neuropsychological evaluation

Study type

Interventional

Funder types

Other

Identifiers

NCT00917709
CHUBX 2008/34

Details and patient eligibility

About

The general aim of this research project is to determine the relationships between alterations of central cholinergic (ACh) and dopaminergic (DA) systems and neurobehavioral features of dementias with Lewy bodies (DLB).

Both clinical and neurochemical data support the view that DLB is not a homogeneous entity and it can be hypothesized that differential alterations of central ACh systems (i.e. anterior vs posterior vs striatal interneurons) in association or not with a DA nigrostriatal dysfunction could partly support the clinical heterogeneity observed in this disease. ACh in vivo imaging has been relatively underutilized to date and to our knowledge only on the postsynaptic side. Furthermore, ACh/DA interactions and their relationships with the symptomatology of DLB and related pathologies (PDD) had never been investigated.

Full description

Neurochemical investigations and observations suggest a crucial physiopathological role of central ACh systems in dementias with Lewy bodies (DLB). Alterations of cholinergic neurons could be involved in the general cognitive decline (central feature) but also in fluctuating attentional performances and rapid eye movement sleep disorder as it was shown in thalamus.

Post synaptic in vivo SPECT imaging recently demonstrated an increase in muscarinic receptors in DLB patients in the occipital cortex that could be associated with the visuospatial dysfunction often reported in DLB or even in visual hallucinations.From a pharmacological point of view, the involvement of ACh systems in DLB is confirmed by the consistently reported efficacy of cholinesterase inhibitor therapy, considered as greater than in AD.

Concerning DA systems, presynaptic in vivo SPECT imaging studies of DA transporter have shown a decreased striatal uptake in DLB patients, different when compared with Parkinson's disease patients or Alzheimer's disease patients.

Strategy, procedure In this project we will use for the first time in vivo molecular imaging of presynaptic molecular target of ACh systems (VAChT) with [123I]-iodobenzovesamicol and of DA systems (DAT) with DATSCAN in order to better analyse the link between neurobehavioral profiles of patients and a differential alteration of ACh/DA systems in DLB.

Enrollment

34 patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients: man or woman probable DLB, with and without extrapyramida syndrome
  • Healthy subjects: man or woman with no neuropsychiatric disorders

Exclusion criteria

  • Diagnostic or therapeutic irradiation during the 12 months before SPECT imaging
  • Age less than 18 and more than 90
  • Iodine sensibility
  • Brain-vascular disease, severe brain injury, type I and II diabetes mellitus, thyroid dysfunction, chronic alcoholism
  • Pregnant and breast feeding women, women in age to procreate
  • Impossibility to undergo MRI study (pace-maker, claustrophobia)
  • Persons under guardianship, outside state to express their assent or in emergency situation
  • Healthy subjects: cognitive impairment, dementia

Trial design

Primary purpose

Health Services Research

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

34 participants in 3 patient groups

DLB with extrapyramidal syndrome
Experimental group
Description:
patients dementia with Lewy bodies with extrapyramidal syndrome
Treatment:
Behavioral: neuropsychological evaluation
Other: Imaging with DATSCAN
Other: Imaging with IBVM
DLB without extrapyramidal syndrome
Other group
Description:
patients dementia with Lewy bodies without extrapyramidal syndrome
Treatment:
Behavioral: neuropsychological evaluation
Other: Imaging with DATSCAN
Other: Imaging with IBVM
healthy volunteers
Sham Comparator group
Description:
healthy volunteers
Treatment:
Behavioral: neuropsychological evaluation
Other: Imaging with DATSCAN
Other: Imaging with IBVM

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems